Twist1 and Y-box-binding protein-1 promote malignant potential in bladder cancer cells

BJU International

Volumn 108, Issue 2 B, 2011, Pages

  Shiota, Masaki ^a   Yokomizo, Akira ^a   Itsumi, Momoe ^a   Uchiumi, Takeshi ^a   Tada, Yasuhiro ^a   Song, Yoohyun ^a   Kashiwagi, Eiji ^a   Masubuchi, Daisuke ^a   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

bladder cancer; cisplatin; doxorubicin; epithelial mesenchymal transition; Twist1; YB 1

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; GREEN FLUORESCENT PROTEIN; LUCIFERASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TWIST 1; UNCLASSIFIED DRUG; Y BOX BINDING PROTEIN 1;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER RESISTANCE; CELL CYCLE; CELL DEATH; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENZYME ASSAY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; ONCOGENE; ONCOGENE TWIST1; ONCOGENE YB 1; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BIOLOGICAL ASSAY; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOXORUBICIN; FLUOROURACIL; HUMANS; NUCLEAR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TWIST TRANSCRIPTION FACTOR; URINARY BLADDER NEOPLASMS; Y-BOX-BINDING PROTEIN 1;

EID: 79960077333     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09810.x     Document Type: Article

References (28)

1. Kaufman DS, Shipley WU, Feldman AS,. Bladder cancer. Lancet 2009; 374: 239-49
2. Ghoneim MA, Abol-Enein H,. Management of muscle-invasive bladder cancer: an update. Nat Clin Pract Urol 2008; 5: 501-8
3. Collaboration ABCM-a. Neoadjubant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003; 361: 1927-34
4. Hussain SA, James ND,. The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 2003; 4: 489-97 (Pubitemid 37009957)
5. Quertermous EE, Hidai H, Blanar MA, Quertermous T,. Cloning and characterization of a basic helix-loop-helix protein expressed in early mesoderm and the developing somites. Proc Natl Acad Sci USA 1994; 91: 7066-70 (Pubitemid 24226803)
6. Hamamori Y, Wu HY, Sartorelli V, Kedes L,. The basic domain of myogenic basic helix-loop-helix (bHLH) proteins is the noble target for direct inhibition by another bHLH protein, Twist. Mol Cell Biol 1997; 17: 6563-73 (Pubitemid 27451203)
7. Yang J, Mani SA, Donaher JL, et al,. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927-39 (Pubitemid 38798858)
8. Wang X, Ling MT, Guan XY, et al,. Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene 2004; 23: 474-82 (Pubitemid 38175002)
9. Wallerand H, Robert G, Pasticier G, et al,. The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. Urol Oncol 2010; 28: 473-9
10. Kwok WK, Ling MT, Lee TW, et al,. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 2005; 65: 5153-62 (Pubitemid 40827324)
11. Hoek K, Rimm DL, Williams KR, et al,. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 2004; 64: 5270-82 (Pubitemid 39006547)
12. Zhang Z, Xie D, Li X, et al,. Significant of TWIST expression and its association with E-cadherin in bladder cancer. Hum Path 2007; 38: 598-606 (Pubitemid 46399887)
13. Fondrevelle ME, Kantelip B, Reiter RE, et al,. The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status. Urol Oncol 2009; 27: 268-76
14. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M,. The pleiotrophic functions of the Y-box-binding protein, YB-1. Bioessays 2003; 25: 691-8 (Pubitemid 36850797)
15. Kuwano M, Oda Y, Izumi H, et al,. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther 2004; 3: 1485-92 (Pubitemid 39562593)
16. Evdokimova V, Tognon C, Ng T, et al,. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 2009; 15: 402-15
17. Astanehe A, Finkbeiner MR, Hojabrpour P, et al,. The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1. Oncogene 2009; 28: 2406-18
18. Shiota M, Izumi H, Onitsuka T, et al,. Twist promotes tumor cell growth through YB-1 expression. Cancer Res 2008; 68: 98-105 (Pubitemid 351380110)
19. Shiota M, Izumi H, Onitsuka T, et al,. Twist and p53 reciprocally regulate target genes through direct interaction. Oncogene 2008; 27: 5543-53
20. Shiota M, Izumi H, Tanimoto A, et al,. Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression through a direct interaction with Twist1 to suppress cancer cell growth. Cancer Res 2009; 69: 3148-56
21. Shiota M, Yokomizo A, Tada Y, et al,. P300/CBP-associated factor regulates Y-box binding protein-1 and promotes cancer cell growth, cancer invasion and drug resistance. Cancer Sci 2010; 101: 1797-806
22. Kawanishi H, Matsui Y, Ito M, et al,. Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer. Clin Cancer Res 2008; 14: 2579-87
23. Nagasawa J, Mizokami A, Koshida K, Yoshida S, Naito K, Namiki M,. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int J Urol 2006; 13: 587-92 (Pubitemid 43760425)
24. Kotoh S, Naito S, Yokomizo A, et al,. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells. Cancer Res 1994; 54: 3248-52 (Pubitemid 24208937)
25. Kotoh S, Naito S, Yokomizo A, Kohno K, Kuwano M, Kumazawa J,. Enhanced expression of gamma-glutamylcysteine synthetase and glutathione S-transferase genes in cisplatin-resistant bladder cancer cells with multidrug resistance phenotype. J Urol 1997; 157: 1054-8 (Pubitemid 27066316)
26. Shiota M, Yokomizo A, Tada Y, et al,. Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene 2010; 29: 237-50
27. Shiota M, Yokomizo A, Tada Y, et al,. Peroxisome proliferator activated receptor γ coactivator-1α interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR. Mol Endocrinol 2010; 24: 114-27
28. Rieger KM, Little AF, Swart JM, et al,. Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. Br J Cancer 1995; 72: 683-90